research Targeted photochemotherapy in alopecia areata
The treatment is a safe and effective option for hair regrowth in patchy alopecia areata.
Search
for
Sort by
Research
330-360 / 1000+ results
research Doxorubicin-induced hair loss in the Angora rabbit: a study of treatments to protect against the hair loss
Vitamin E in the diet might help protect against hair loss caused by the chemotherapy drug doxorubicin in rabbits.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research Trichoblastic Carcinoma (“Malignant Trichoblastoma”) with Lymphatic and Hematogenous Metastases
Long-standing benign tumors can become cancerous, especially in people with weakened immune systems.
research Hair Follicle–Derived Blood Vessels Vascularize Tumors in Skin and Are Inhibited by Doxorubicin
Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research COMPARATIVE EVALUATION OF EFFICACY AND SAFETY OF TOPICAL METHOTREXATE WITH TRETINOIN VERSUS BETAMETHASONE WITH TRETINOIN IN PATIENTS OF ALOPECIA AREATA: A PROSPECTIVE RANDOMIZED DOUBLE-BLIND STUDY
Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
research Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene
The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
research Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata
Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
research Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss
Chemotherapy for breast cancer often causes significant and lasting hair loss.
research Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors
Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
Early intervention and tailored management are crucial for skin side effects in cancer treatments.
research Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
EGFR inhibitors for lung cancer can cause severe skin issues.
research The use of botulinum toxin in the treatment of androgenetic alopecia
research Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin
Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research Topical RT1640 treatment effectively reverses gray hair and stem cell loss in a mouse model of radiation‐induced canities
RT1640 treatment reverses gray hair and promotes hair growth in mice.
research Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
Early intervention and tailored management can reduce skin side effects from cancer treatments.
research 440 Squaric acid dibutylester, used in alopecia areata immunotherapy, promotes innate immune-driven hair growth with CD206+ macrophage accumulation in the dermis
research Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research Dermoscopy — 4th Conference of the Section of Dermoscopy and Other Skin Imaging Techniques (DiTOS) of the Polish Dermatological Society — Abstracts
Hair loss can be caused by cancer, treatments, or skin conditions, and trichoscopy helps diagnose it.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research PCA: A tFNA-based targeted nucleic acid nanocomposite hydrogel for the treatment of androgenetic alopecia through the promotion of angiogenesis and hair follicle stem cell proliferation
PCA hydrogel promotes hair growth by enhancing blood vessel formation and hair follicle stem cell activity.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.